Literature DB >> 10336580

The influence of CYP2D6 activity on the kinetics of propafenone enantiomers in Chinese subjects.

W M Cai1, B Chen, M H Cai, Y Chen, Y D Zhang.   

Abstract

AIMS: To determine role of CYP2D6 activity in the pharmacokinetics of propafenone (PPF) enantiomers in native Chinese subjects.
METHODS: Sixteen extensive metabolizers (EMs) and one poor metabolizer (PM), whose phenotype had been previously assessed with dextromethorphan metabolic phenotyping, were enrolled. Blood samples (0 approximately 15 h) were taken after oral administration of a single dose (400 mg) of racemic-propafenone hydrochloride. A reverse-phase h.p.l.c. method with pre-column derivatization was employed to quantitate enantiomeric concentrations of propafenone in plasma.
RESULTS: For the EM subjects, S-PPF was less rapidly metabolized and had higher peak plasma concentrations than R-PPF (413+/-143 vs 291+/-109 ng ml-1, P<0.001). The AUC was markedly higher for S-PPF than for R-PPF (2214+/-776 vs 1639+/-630 microg h l-1, P<0.001), whereas the clearance of S-PPF was significantly lower than that of R-PPF (96.0+/-39.0 vs 138+/-78 l h-1, P<0.01). There were no differences in t1/2, and Cmax between the two isomers (P >0.05). In the one PM subject, not only did S-PPF appear to undergo less rapid metabolism than R-PPF, but the subject also showed 2 approximately 3 fold differences in Cmax, CL and AUC compared with EMs. The correlation coefficients (rs ) between dextromethorphan metabolic ratio (lg MR) and pharmacokinetic parameters (Cmax, CL and AUC) were 0.63, -0.87, 0.87 for S-PPF and 0. 57, -0.73, 0.86 for R-PPF, respectively.
CONCLUSIONS: Our results suggest that CYP2D6 activity contributes to the pharmacokinetic variability of propafenone enantiomers in Chinese subjects.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10336580      PMCID: PMC2014184          DOI: 10.1046/j.1365-2125.1999.00932.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  6 in total

1.  Stereoselective disposition and pharmacologic activity of propafenone enantiomers.

Authors:  H K Kroemer; C Funck-Brentano; D J Silberstein; A J Wood; M Eichelbaum; R L Woosley; D M Roden
Journal:  Circulation       Date:  1989-05       Impact factor: 29.690

2.  [A non-linear method and its program for calculating pharmacokinetic parameters].

Authors:  Y C Yang; G Chen; L Yuan
Journal:  Zhongguo Yao Li Xue Bao       Date:  1983-12

3.  Dextromethorphan metabolic phenotyping in a Chinese population.

Authors:  W M Cai; B Chen; Y X Liu; X Chu
Journal:  Zhongguo Yao Li Xue Bao       Date:  1997-09

Review 4.  Clinical pharmacokinetics of propafenone.

Authors:  J T Hii; H J Duff; E D Burgess
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

5.  Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences.

Authors:  L A Siddoway; K A Thompson; C B McAllister; T Wang; G R Wilkinson; D M Roden; R L Woosley
Journal:  Circulation       Date:  1987-04       Impact factor: 29.690

6.  Steady-state plasma concentrations of propafenone--chirality and metabolism.

Authors:  M Volz; V Mitrovic; M Schlepper
Journal:  Int J Clin Pharmacol Ther       Date:  1994-07       Impact factor: 1.366

  6 in total
  6 in total

Review 1.  Impact of stereoselectivity on the pharmacokinetics and pharmacodynamics of antiarrhythmic drugs.

Authors:  Reza Mehvar; Dion R Brocks; Majid Vakily
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Chiral metabolism of propafenone in rat hepatic microsomes treated with two inducers.

Authors:  Q Zhou; T W Yao; S Zeng
Journal:  World J Gastroenterol       Date:  2001-12       Impact factor: 5.742

3.  Metabolism of propafenone and verapamil by cryopreserved human, rat, mouse and dog hepatocytes: comparison with metabolism in vivo.

Authors:  B Reder-Hilz; M Ullrich; M Ringel; N Hewitt; D Utesch; F Oesch; J G Hengstler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-03-04       Impact factor: 3.000

Review 4.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

5.  Influence of CYP2D6 genetic variation on adverse events with propafenone in the pediatric and young adult population.

Authors:  Sudeep D Sunthankar; Prince J Kannankeril; Andrea Gaedigk; Andrew E Radbill; Frank A Fish; Sara L Van Driest
Journal:  Clin Transl Sci       Date:  2022-05-26       Impact factor: 4.438

Review 6.  The Effect of CYP2D6 Phenotypes on the Pharmacokinetics of Propafenone: A Systematic Review and Meta-Analysis.

Authors:  Quyen Thi Tran; In-Hwan Baek; Na-Young Han; Hwi-Yeol Yun; Jung-Woo Chae
Journal:  Pharmaceutics       Date:  2022-07-11       Impact factor: 6.525

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.